vatalanib has been researched along with Brain Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhardwaj, RD; Gnimpieba, EZ; Hoffman, MM; Messerli, SM | 1 |
| Achyut, BR; Angara, K; Ara, R; Arbab, AS; Bollag, RJ; Borin, TF; Iskander, A; Lebedyeva, I; Lin, PC; Rashid, MH | 1 |
| Chamberlain, M; Chandler, JP; Grimm, SA; Helenowski, I; Johnston, SK; McCarthy, K; Mrugala, MM; Muro, K; Rademaker, A; Raizer, JJ; Rice, L | 1 |
| Achyut, BR; Angara, K; Ara, R; Arbab, AS; Borin, TF; Iskander, A; Jain, M; Rashid, MH; Shankar, A | 1 |
| Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ | 1 |
| Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ | 1 |
| Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L | 1 |
| Dai, C; Draghi, N; Eklöf, C; Holland, EC; Liang, X; Resh, MD; Uhrbom, L; Westermark, B; Wolf, RM | 1 |
| Huang, S; Kim, LS; Lev, DC; Lu, W; Price, JE | 1 |
| Bendszus, M; Goldbrunner, RH; Kiderlen, M; Sasaki, M; Tonn, JC; Wood, J | 1 |
| Choma, M; Cole, P; Kealey, S; Moya, MG; Parks, L; Provenzale, JM; Serajuddin, H; York, G | 1 |
5 trial(s) available for vatalanib and Brain Neoplasms
| Article | Year |
|---|---|
A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Meningioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Phthalazines; Pyridines; Salvage Therapy; Time Factors | 2014 |
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome | 2009 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Pyridines; Radiotherapy, Adjuvant; Temozolomide; Treatment Outcome | 2010 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Membrane Proteins; Middle Aged; Phthalazines; Polymorphism, Single Nucleotide; Pyridines; Radiotherapy; Receptor, TIE-2; Temozolomide; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Topics: Adult; Angiogenesis Inhibitors; Blood Volume; Blood-Brain Barrier; Brain; Brain Neoplasms; Capillary Permeability; Cerebrovascular Circulation; Contrast Media; Female; Gadolinium DTPA; Glioblastoma; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Phthalazines; Pyridines | 2006 |
7 other study(ies) available for vatalanib and Brain Neoplasms
| Article | Year |
|---|---|
Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Proliferation; Child, Preschool; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Male; Molecular Targeted Therapy; Phthalazines; Prognosis; Pyridines; Receptor Protein-Tyrosine Kinases; Rhabdoid Tumor; RNA, Small Interfering; Teratoma | 2017 |
CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Interleukin-8; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Phthalazines; Pyridines; Rats, Nude; Receptors, Interleukin-8B; Tissue Array Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.
Topics: Amidines; Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Nude | 2017 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Glioma; Humans; Lactic Acid; Male; Neovascularization, Pathologic; Phthalazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyridines; Rats; Rats, Sprague-Dawley; Temozolomide; Treatment Outcome | 2010 |
p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3.
Topics: Animals; Brain Neoplasms; Cell Differentiation; Cells, Cultured; Chromosomes, Human, Pair 19; DNA-Binding Proteins; Down-Regulation; Genes, Tumor Suppressor; Glioma; GTPase-Activating Proteins; Guanine Nucleotide Exchange Factors; Humans; Intermediate Filament Proteins; Mice; Mice, Inbred Strains; Nerve Tissue Proteins; Nestin; Nuclear Proteins; Oligodendroglioma; Phthalazines; Platelet-Derived Growth Factor; Pyridines; Repressor Proteins; Retroviridae | 2003 |
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal; Carotid Artery, Internal; Cell Hypoxia; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Injections, Intra-Arterial; Interleukin-8; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Division; Cell Survival; Glioma; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |